Zinc acetate

Overview

No overview information available.

Indication

Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections .

Associated Conditions

Pruritus
Skin Irritation
Oozing and weeping
Pain and itching

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders	2024/05/14	NCT06412653	Phase 2	Not yet recruiting	Children's University Hospital Cologne, Germany
Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers	2016/08/16	NCT02868151	Phase 2	Completed	Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency	2015/01/13	NCT02337569	Phase 3	Completed	Nobelpharma
Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency	2014/12/22	NCT02321865	Phase 3	Completed	Nobelpharma
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy	2008/06/12	NCT00696410	Phase 1	Completed	University of Michigan
The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children	2006/09/07	NCT00373100	Phase 3	Completed	Makerere University
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.	2005/09/21	NCT00212355	Phase 3	Completed	Nobelpharma
Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.	2005/09/21	NCT00212368	Phase 3	Completed	Nobelpharma
Study of Zinc for Wilson Disease	1999/10/19	NCT00004338	Phase 4	Completed	National Center for Research Resources (NCRR)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Itch Relief	The Kroger Co	59450-295	TOPICAL	1 mg in 1 mL	3/31/2025
foster and thrive anti itch cream	Strategic Sourcing Services LLC	70677-1289	TOPICAL	0.1 g in 100 g	4/30/2025
GALZIN	Teva Pharmaceuticals USA, Inc.	57844-208	ORAL	50 mg in 1 1	8/16/2023
Clear Anti-Itch	Retail Business Services, LLC	72476-218	TOPICAL	1 mg in 1 mL	7/7/2025
Clear Anti-Itch	Perrigo Direct, Inc.	75981-218	TOPICAL	1 mg in 1 mL	8/26/2025
GALZIN	Teva Pharmaceuticals USA, Inc.	57844-215	ORAL	25 mg in 1 1	8/16/2023
Clear Anti Itch	United Natural Foods, Inc. dba UNFI	41163-099	TOPICAL	1 mg in 1 mL	7/7/2025
Itch Relief	Meijer Distribution, Inc	41250-295	TOPICAL	1 mg in 1 mL	8/11/2025
Itch Relief	Retail Business Services, LLC	72476-295	TOPICAL	1 mg in 1 mL	7/7/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
NUTRIFLEX® OMEGA SPECIAL EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN15469P	INJECTION, EMULSION	7.024mg/1000ml	4/23/2018
NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN15468P	INJECTION, EMULSION	5.264mg/1000ml	4/23/2018
NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN16734P	INJECTION, EMULSION	7.024mg/1000ml	3/7/2023

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
CLEAR ANTI-ITCH LOTION	lander co. canada limited	02244180	Lotion - Topical	0.1 %	10/2/2001
TEMPRA CEMENT POWDER AND TEMPRA POLY LIQUID	Germiphene Corporation	00231827	Powder , Liquid - Dental	2.8 G / 100 G	12/31/1971
CLEAR ANTI-ITCH LOTION	perrigo international	02230493	Lotion - Topical	0.1 %	8/17/1998
ITCH RELIEF LOTION	crls	02318423	Lotion - Topical	0.1 % / W/W	9/9/2009
BENADRYL SPRAY	mcneil consumer healthcare division of johnson & johnson inc	02280876	Spray - Topical	0.1 %	3/9/2007
ITCH RELIEF SPRAY	tender corporation	02376148	Aerosol - Topical	0.1 % / W/V	N/A
ALLERGY CREAM	g&w laboratories inc.	02246391	Cream - Topical	0.1 %	7/22/2003
BENADRYL ITCH STOPPING CREAM	kenvue canada inc.	02484838	Cream - Topical	0.1 %	1/13/2020
DERMAGRAN MOISTURIZING SPRAY	canadian medical supply inc.	00701726	Spray - Topical	.15 MG / 30 ML	12/31/1987
ANTI-ITCH PLUS CREAM	Taro Pharmaceuticals Inc	02301717	Cream - Topical	0.1 %	N/A

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
PEDIAVEN G20 SOLUCION PARA PERFUSION	Fresenius Kabi España, S.A.U.	78951	SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized
ISOPLASMAL G SOLUCION PARA PERFUSION	B Braun Medical S.A.	59737	SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized
NUTRIFLEX LIPID PLUS EMULSION PARA PERFUSION	B. Braun Melsungen Ag	62989	EMULSIÓN PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized
NUTRIFLEX LIPID SPECIAL EMULSION PARA PERFUSION	B. Braun Melsungen Ag	62998	EMULSIÓN PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized
ZINERYT 40 MG/ML + 12 MG/ML POLVO Y DISOLVENTE PARA SOLUCIÓN CUTÁNEA	Cheplapharm Arzneimittel Gmbh	62133	SOLUCIÓN CUTÁNEA	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Eton Pharmaceuticals Poised for Growth with Expanding Rare Disease Portfolio and Pending FDA Approvals

6 months ago

Eton Pharmaceuticals is anticipating FDA approval for ET-400 in early June, with commercial launch planned immediately following approval and significant revenue impact expected in Q3 and Q4 2025.

Eton Pharmaceuticals Launches FDA-Approved Galzin for Wilson Disease Maintenance Treatment

6 months ago

Eton Pharmaceuticals has launched Galzin (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease maintenance treatment, offering improved access through their specialty pharmacy network.

FDA Extends Review Period for Eton Pharmaceuticals' Rare Disease Drug ET-400

7 months ago

The FDA has extended the PDUFA goal date for Eton Pharmaceuticals' ET-400 New Drug Application to May 28, 2025, requiring additional time to review supplemental information.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access